Probiotics as a Therapeutic Approach in Treatment of Inflammatory Bowel Disease

Main Article Content

Uzma Parveen
Ruqaiah Farooq


Inflammatory bowel disease is an immune mediated chronic inflammatory disorder, wherein including Ulcerative colitis, Crohn disease these are two major phenotypes of Inflammatory Bowel Disease. Even though the mechanism of Inflammatory disease is still unclear, probiotic strains have found to have a potential effect in management of the disease. Until now, remarkable advancement has been elucidated in the treatment, however, numerous alternative choices are persistently hunted that might prevent remission of disease. Probiotics are described as living organisms that act as a driving force, wherein exerting health benefits beyond primary nourishment. In view of clinical perspective the efficacy of probiotics seems to be absolutely robust in terms of experimental analysis. Moreover, there is a substantial rise in evidence that probiotics may likely modify the disease manifestations including animal models and in those suffering from Inflammatory Bowel Disease. Considerably, the effect might occur due to divergence in concentration of micro organism used and the vulnerability of the progression of disease is managed .In striking contrast, due to ambiguous research in sequencing technology has conditionally led to the recognition of gut microbiota framework of IBD. Numerous clinical trials depicted the use of probiotics, dysbiosis, microbiota as promising therapies in Inflammatory Bowel Disease. This review elucidates about the role of probiotics, its beneficial effects, summary of literature review in treatment of Inflammatory bowel disease.

Inflammatory disorder, probiotics, gut microbiota, manifestations, experimental analysis.

Article Details

How to Cite
Parveen, U., & Farooq, R. (2020). Probiotics as a Therapeutic Approach in Treatment of Inflammatory Bowel Disease. Asian Journal of Research and Reports in Gastroenterology, 3(3), 1-7. Retrieved from
Review Article


Rao TP, Quartarone G. Role of guar fiber in improving digestive health and function. Nutrition. 2019;59:158-69.

Matsuoka K, Kanai T. The gut microbiota and inflammatory bowel disease. In Seminars in immunopathology. Springer Berlin Heidelberg. 2015;37(1):47-55.

Abautret-Daly Á, Dempsey E, Parra-Blanco A, Medina C, Harkin A. Gut–brain actions underlying comorbid anxiety and depression associated with inflammatory bowel disease. Acta Neuropsychiatrica. 2018;30(5):275-96.

Rosa R, Ornella R, Maria GC, Elisa S, Maria N, Chiara M, Antonio N, Tiziana M, Gian LD, Francesco DM, Gioacchino L. The role of diet in the prevention and treatment of Inflammatory Bowel Diseases. Acta Bio-medica: Atenei Parmensis. 2018; 89(Suppl 9):60.

Guandalini S, Sansotta N. Probiotics in the treatment of inflammatory bowel disease. Probiotics and child gastrointestinal health: Advances in Microbiology, Infectious Diseases and Public Health. 2019;10:101-7.

Danese S, Fiocchi C. Etiopathogenesis of inflammatory bowel diseases. World Journal of Gastroenterology: WJG. 2006; 12(30):4807.

Kugathasan S, Fiocchi C. Progress in basic inflammatory bowel disease research. In Seminars in Pediatric Surgery. WB Saunders. 2007;16(3):146-153.

Podolsky DK. Inflammatory bowel disease. New England Journal of Medicine. 1991; 325(13):928-37.

Bouma G, Strober W. The immunological and genetic basis of inflammatory bowel disease. Nature Reviews Immunology. 2003;3(7):521-33.

Westall FC. Integrating theories of the etiology of Crohn's disease on the etiology of Crohn's disease: Questioning the hypotheses. William M. Chamberlin, Saleh A. Naser Med Sci Monit, 2006;12(2): RA27-33. Medical Science Monitor. 2006; 12(5):LE5-6.

Wedlake L, Slack N, Andreyev HJ, Whelan K. Fiber in the treatment and maintenance of inflammatory bowel disease: A systematic review of randomized controlled trials. Inflamm Bowel Dis. 2014;20:576-586.

Talley NJ, Abreu MT, Achkar JP, Bernstein CN, Dubinsky MC, Hanauer SB, Kane SV, Sandborn WJ, Ullman TA, Moayyedi P. American College of Gastroenterology IBD Task Force. An evidence-based systematic review on medical therapies for inflammatory bowel disease. Am J Gastroenterol; 2011.

Gearry RB. IBD and environment: Are there differences between east and west. Digest. Dis. 2016;34:84-89.

Kostic AD, Xavier RJ, Gevers D. The microbiome in inflammatory bowel disease: Status and the future ahead. Gastroenterology. 2014;146:1489-1499.

Lee D, Albenberg L, Compher C, Baldassano R, Piccoli D, Lewis JD, Wu GD. Diet in the pathogenesis and treatment of inflammatory bowel diseases. Gastroenterology. 2015;148:1087-1106.

Liu JZ, van Sommeren S, Huang H, et al. Association analyses identify 38 susceptibility loci for inflammatory bowel disease and highlight shared genetic risk across populations. Nat Genet. 2015; 47(9):979–86.

Goldsmith JR, Sartor RB. The role of diet on intestinal microbiota metabolism: Downstream impacts on host immune function and health, and therapeutic implications. J Gastroenterol. 2014;49(5): 785–98.

Sheehan D, Moran C, Shanahan F. The microbiota in inflammatory bowel disease. J Gastroenterol. 2015;50(5):495–507.

Eckburg PB et al. Diversity of the human intestinal microbial flora. Science. 2005; 308:1635–1638.

Frank DN et al. Molecular-phylogenetic characterization of microbial community imbalances in human inflammatory bowel diseases. Proc Natl Acad Sci USA. 2007; 104:13780–13785.

Fiorucci S, Distrutti E, Mencarelli A, Barbanti M, Palazzini E, Morelli A. Inhibition of intestinal bacterial translocation with rifaximin modulates lamina propria monocytic cells reactivity and protects against inflammation in a rodent model of colitis. Digestion. 2002; 66:246–256.

Frank DN, Robertson CE, Hamm CM, Kpadeh Z, Zhang T, Chen H, Zhu W, Sartor RB, Boedeker EC, Harpaz N, Pace NR, Li E. Disease phenotype and genotype are associated with shifts in intestinal associated microbiota in inflammatory bowel diseases. Inflamm Bowel Dis. 2011;17:179–184.

Sokol H, Seksik P, Rigottier-Gois L, Lay C, Lepage P, Podglajen I, Marteau P, Dore J. Specificities of the faecal microbiota in inflammatory bowel disease. Inflamm Bowel Dis. 2006;12:106–111.

Martinez C, Antolin M, Santos J, Torrejon A, Casellas F, Borruel N, Guarner F, Malagelada JR. Unstable composition of the fecal microbiota in ulcerative colitis during clinical remission. Am J Gastroenterol. 2008;103:643–648.

Schrezenmeir J, de Vrese M. Probiotics, prebiotics, and synbiotics— approaching a definition. Am J Clin Nutr. 2001;73(2 Suppl):361s–4s.

Hamilton-Miller JM, Gibson GR, Bruck W. Some insights into the derivation and early uses of the word ‘probiotic’. Br. J. Nutr. 2003;90:845.

Fontana L, Bermudez-Brito M, Plaza-Diaz J, Muñoz-Quezada S, Gil A. Sources, isolation, characterisation, and evaluation of probiotics. Br. J. Nutr. 2013;109:35–50.

Gibson GR, Roberfroid MB. Dietary modulation of the human colonic microbiota: Introducing the concept of prebiotics. J. Nutr. 1995;125:1401–1412.

Ouwehand AC, Salminen S, Isolauri E. Probiotics: An overview of beneficial effects. Antonie Van Leeuwenhoek. 2002; 82:279–289.

Shanahan F. Probiotics in inflammatory bowel disease. Gut.2001;48:609.

[PMID: 11302956]

Shanahan F. Probiotics and inflammatory bowel disease: Is there a scientific rationale? Inflamm Bowel Dis. 2000;6:107-115

[PMID: 10833070]

Asahara T, Shimizu K, Nomoto K, Hamabata T, Ozawa A, TakedaY. Probiotic bifidobacteria protect mice from lethal infection with Shiga toxin-producing Escherichia coli O157: H7. Infect Immun. 2004;72:2240-2247.

Venturi A, Gionchetti P, Rizzello F, Johansson R, Zucconi E, Brigidi P, Matteuzzi D, Campieri M. Impact on the composition of the faecal flora by a new probiotic preparation: preliminary data on maintenance treatment of patients with ulcerative colitis. Aliment Pharmacol Ther. 1999;13

Sood A, Midha V, Makharia GK, et al. The probiotic preparation, VSL#3 induces remission in patients with mild-to-moderately active ulcerative colitis. Clin Gastroenterol Hepatol. 2009;7(11):1202–1209.

Ng SC, Plamondon S, Kamm MA, Hart AL, Al-Hassi HO, Guenther T, et al. Immunosuppressive effects via human intestinal dendritic cells of probiotic bacteria and steroids in the treatment of acute ulcerative colitis. Inflamm Bowel Dis. 2010;16:1286-1298.

Guslandi M, Mezzi G, Sorghi M, Testoni PA.Saccharomyces boulardii in maintenance treatment of Crohn’s disease. Dig Dis Sci. 2000;45:1462–1464.

Petersen AM, Mirsepasi H, Halkjaer SI, Mortensen EM, Nordgaard-Lassen I, Krogfelt KA. Ciprofloxacin and probiotic Escherichia coli nissle add-on treatment in active ulcerative colitis: A double-blind randomized placebo controlled clinical trial. J CrohnsColitis. 2014;8:1498–1505.

Zocco MA, dal Verme LZ, Cremonini F, et al. Efficacy of Lactobacillus GG in maintaining remission of ulcerative colitis. Aliment Pharmacol Ther. 2006;23(11): 1567–74.

Mallon P, McKay D, Kirk S, et al. Probiotics for induction of remission in ulcerative colitis. Cochrane Database Syst Rev. 2007;4:Cd005573.

Tamaki H, Nakase H, Inoue S, Kawanami C, Itani T, Ohana M, Kusaka T, Uose S, Hisatsune H, Tojo M, et al. Efficacy of probiotic treatment with Bifidobacterium longum 536 for induction of remission in active ulcerative colitis: A randomized, double-blinded, placebo-controlled multi-center trial. Dig. Endosc. 2016;28:67–74.

Yoshimatsu Y, Yamada A, Furukawa R, Sono K, Osamura A, Nakamura K, Aoki H, Tsuda Y, Hosoe N, Takada N, et al. Effectiveness of probiotic therapy for the prevention of relapse in patients within active ulcerative colitis. World J. Gastro-enterol. 2015;21:5985–5994.

Krag A, Munkholm P, Israelsen H, von Ryberg B. Andersen KK, Bendtsen F. Profermin is efficacious inpatients with active ulcerative colitis-A randomized controlled trial. Inflamm. Bowel Dis. 2013; 19:2584–2592.

Petersen AM, Mirsepasi H, Halkjær SI, Mortensen EM, Nordgaard-Lassen I, Krogfelt KA. Ciprofloxacin and probiotic Escherichia coli Nissle add-on treatment in active ulcerative colitis: A double-blind randomized placebo controlled clinical trial. J. Crohns Colitis. 2014;8:1498–1505.

Hevia A, López P, Suárez A, Jacquot C, Urdaci MC, Margolles A, Sánchez B. Association of levels of antibodies from patients with inflammatory bowel disease with extracellular proteins of food and probiotic bacteria. Biomed. Res. Int. 2014; 2014:351204.

Astó E, Méndez I, Audivert S, Farran-Codina A, Espadaler J. The efficacy of probiotics, prebiotic inulin-type fructans, and synbiotics in human ulcerative colitis: a systematic review and meta-analysis. Nutrients. 2019;11:293.

Peng L, Zhong Y, Wang A, Jiang Z. Probiotics combined with aminosalicylic acid affiliates remission of ulcerative colitis: A meta-analysis of randomized controlled trial. Bioscience Reports. 2019; 39(1).

Chen MY, Qiu ZW, Tang HM, Zhuang KH, Cai QQ, Chen XL, Li HB. Efficacy and safety of bifid triple viable plus aminosalicylic acid for the treatment of ulcerative colitis: A systematic review and meta-analysis. Medicine. 2019;98(47).

Jia K, Tong X, Wang R, Song X. The clinical effects of probiotics for inflammatory bowel disease: A meta-analysis. Medicine. 2018;97(51).

Triantafillidis JK, Tzouvala M, Triantafyllidi E. Enteral nutrition supplemented with transforming growthfactor-β, colostrum, probiotics, and other nutritional compounds in the treatment of patients with inflammatory bowel disease. Nutrients. 2020;12(4):1048.